Raphael Pharmaceutical (RAPH) Invested Capital (2020 - 2026)
Raphael Pharmaceutical's (RAPH) quarterly Invested Capital came in at $778000.0 in Q2 2026, up 275.62% year-over-year from $207123.8 in Q2 2025, and up 57.81% quarter-over-quarter from $493000.0 in Q4 2025.
Powered by 
Analysis
Raphael Pharmaceutical (RAPH) Invested Capital (2020 - 2026) Analysis & Trends
Raphael Pharmaceutical has disclosed Invested Capital across 7 years of filings, most recently posting $778000.0 for Q2 2026.
- In Q2 2026, Invested Capital rose 275.62% year-over-year to $778000.0; the TTM figure through Jun 2026 stood at $778000.0 (up 275.62% YoY), while the FY2025 annual figure was $493000.0, up 301.22% from the prior year.
- Invested Capital came in at $778000.0 for Q2 2026 at Raphael Pharmaceutical, up from $493000.0 in the prior quarter.
- In the past five years, Invested Capital ranged from a high of $778000.0 in Q2 2026 to a low of -$486000.0 in Q3 2024.
- Average Invested Capital over 5 years is -$34200.0, with a median of -$35000.0 recorded in 2023.
- Year-over-year, Invested Capital plunged 1288.57% in 2024 and surged 301.22% in 2025.
- Over 5 years, Invested Capital stood at $112000.0 in 2022, then surged by 63.39% to $183000.0 in 2023, then sank by 233.88% to -$245000.0 in 2024, then jumped by 301.22% to $493000.0 in 2025, then surged by 57.81% to $778000.0 in 2026.
- Per Business Quant data, the three most recent Invested Capital figures were $778000.0 in Q2 2026, $493000.0 in Q4 2025, and -$468000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 74.44 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 40.49 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 33.70 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 7.35 Bn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 26.94 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Raphael Pharmaceutical | 28.25 Mn | 28.25 Mn | - | 778,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 778,000.00 |
| Dec 31, 2025 | 493,000.00 |
| Sep 30, 2025 | -468,000.00 |
| Jun 30, 2025 | -443,000.00 |
| Mar 31, 2025 | -286,000.00 |
| Dec 31, 2024 | -245,000.00 |
| Sep 30, 2024 | -486,000.00 |
| Jun 30, 2024 | -264,000.00 |
| Mar 31, 2024 | -66,000.00 |
| Dec 31, 2023 | 183,000.00 |
| Sep 30, 2023 | -35,000.00 |
| Jun 30, 2023 | -22,000.00 |
| Dec 31, 2022 | 112,000.00 |
| Jun 30, 2022 | 132,000.00 |
| Mar 31, 2022 | 104,000.00 |
| Dec 31, 2021 | 150,000.00 |
| Dec 31, 2020 | 671,000.00 |